Evidence map›Paper›PMID 37121213›Full record

ArticleLung cancer (Amsterdam, Netherlands)2023

Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas.

Gavitt A Woodard, Vivianne Ding, Christina Cho, Nathan R Brand, Johannes R Kratz, Kirk D Jones, David M Jablons

Open access · hybridAbstract read
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Pathological Features and Differential Efficacy of Cisplatin-Based Adjuvant Chemotherapy in Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gavitt A WoodardUniversity of California, San Francisco, Department of Surgery, Division of Adult Cardiothoracic Surgery, 500 Parnassus Avenue, Room MUW-424, San Francisco, CA 94143-1724, United States. Electronic address: gavitt.woodard@yale.edu.
Vivianne DingUniversity of California, San Francisco, Department of Surgery, Division of Adult Cardiothoracic Surgery, 500 Parnassus Avenue, Room MUW-424, San Francisco, CA 94143-1724, United States.
Christina ChoYale Cancer Center, Department of Immunobiology, 333 Cedar Street, New Haven, CT 06520, United States.
Nathan R BrandUniversity of California, San Francisco, Department of Surgery, Division of Adult Cardiothoracic Surgery, 500 Parnassus Avenue, Room MUW-424, San Francisco, CA 94143-1724, United States.
Johannes R KratzUniversity of California, San Francisco, Department of Surgery, Division of Adult Cardiothoracic Surgery, 500 Parnassus Avenue, Room MUW-424, San Francisco, CA 94143-1724, United States.
Kirk D JonesUniversity of California, San Francisco, Department of Pathology, 505 Parnassus Avenue Suite M590, Box 0511, San Francisco, CA 94143, United States.
David M JablonsUniversity of California, San Francisco, Department of Surgery, Division of Adult Cardiothoracic Surgery, 500 Parnassus Avenue, Room MUW-424, San Francisco, CA 94143-1724, United States.
University of California, San Francisco · USYale Cancer Center · US

Funding

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1M
NCI NIH HHS P50 CA196530
6 · The paper itself

Abstract

backgroundGenetic changes that drive the transition from lepidic to invasive cancer development within a radiographic ground glass or semi-solid lung lesion (SSL) are not well understood. Biomarkers to predict the transition to solid, invasive cancer within SSL are needed.

methodsPatients with surgically resected SSL were identified retrospectively from a surgical database. Clinical characteristics and survival were compared between stage I SSL (n = 65) and solid adenocarcinomas (n = 120) resected during the same time period. Areas of normal lung, in situ lepidic, and invasive solid tumor were microdissected from within the same SSL specimens and next generation sequencing (NGS) and Affymetrix microarray of gene expression were performed.

resultsThere were more never smokers, Asian patients, and sub-lobar resections among SSL but no difference in 5-year survival between SSL and solid adenocarcinoma. Driver mutations found in both lepidic and solid invasive portion were EGFR (43%), KRAS (21%), and DNMT3A (5%). CEACAM5 was the most upregulated gene found in solid, invasive portions of SSL. Lepidic and invasive solid areas had many similarities in gene expression, however there were some significant differences with the gene SPP1 being a unique biomarker for the invasive component of a SSL.

conclusionsCommon lung cancer driver mutations are present in in situ lepidic as well as invasive solid portions of a SSL, suggesting early development of driver mutations. CEACAM5 and SPP1 emerged as promising biomarkers of invasive potential in semi-solid lesions. Other studies have shown both genes to correlate with poor prognosis in lung cancer and their role in evolution of semi-solid lung lesions warrants further study.

Indexed as

AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsGenomicsHumansRetrospective StudiesAdenocarcinoma in situGround glass opacityLung adenocarcinomaMicroarrayNext generation sequencingSemi-solid lung nodules

Identifiers

PMID37121213
PMCPMC10900430
OpenAlexW4366606793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.